{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:12:06Z","timestamp":1787497926633,"version":"build-2736575974"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015806","name":"Project for Key Medicine Discipline Construction of Guangzhou Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Paroxetine is one of the most potent selective serotonin reuptake inhibitors (SSRIs) approved for treating depression, panic disorder, and obsessive-compulsive disorder. There is evidence linking genetic polymorphisms and nonlinear metabolism to the Paroxetine\u2019s pharmacokinetic (PK) variability. The purpose of the present study was to develop a population PK (PPK) model of paroxetine in Chinese patients, which was used to define the paroxetine\u2019s PK parameters and quantify the effect of clinical and baseline demographic factors on these PK characteristics. The study included 184 inpatients with psychosis (103 females and 81 males), with a total of 372 serum concentrations of paroxetine for PPK analyses. The total daily dosage ranged from 20 to 75\u00a0mg. One compartment model could fit the PKs characterize of paroxetine. Covariate analysis revealed that dose, formulation, and sex had a significant effect on the PK parameters of paroxetine; however, there was no evident genetic influence of\n                    <jats:italic>CYP2D6<\/jats:italic>\n                    enzymes on paroxetine concentrations in Chinese patients. The study determined that the population\u2019s apparent distribution volume (V\/F) and apparent clearance (CL\/F), respectively, were 8850 and 21.2\u00a0L\/h. The CL\/F decreased 1-2-fold for each 10\u00a0mg dose increase, whereas the different formulations caused a decrease in V\/F of 66.6%. Sex was found to affect bioavailability (F), which decreased F by 47.5%. Females had higher F values than males. This PPK model described data from patients with psychosis who received paroxetine immediate-release tablets (IR-T) and\/or sustained-release tablets (SR-T). Paroxetine trough concentrations and relative bioavailability were different between formulations and sex. The altered serum concentrations of paroxetine resulting from individual variants and additive effects need to be considered, to optimize the dosage regimen for individual patients.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.966622","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:55:43Z","timestamp":1662944143000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetics of immediate and sustained-release formulations of paroxetine: Population pharmacokinetic approach to guide paroxetine personalized therapy in chinese psychotic patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiao-lin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-qing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-pei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-jia","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-guan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-wei","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1527-3458.2001.tb00189.x","article-title":"Paroxetine: a review","volume":"7","author":"Bourin","year":"2001","journal-title":"CNS Drug Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1515\/dmdi-2014-0029","article-title":"Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland","volume":"30","author":"Brosen","year":"2015","journal-title":"Drug Metab. Pers. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"491895","DOI":"10.3389\/fgene.2020.491895","article-title":"How can drug metabolism and transporter genetics inform psychotropic prescribing?","volume":"11","author":"Carvalho Henriques","year":"2020","journal-title":"Front. Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.5414\/cp203008","article-title":"Polymorphism in CYP2D6 affects the pharmacokinetics and dose escalation of paroxetine controlled-release tablet in healthy Chinese subjects","volume":"55","author":"Chen","year":"2017","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B5","first-page":"14","article-title":"Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea","volume":"64","author":"DeVane","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2125.2006.02629.x","article-title":"Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling","volume":"61","author":"Feng","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/sj.npp.1300960","article-title":"Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder","volume":"31","author":"Findling","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/00004583-199908000-00010","article-title":"Paroxetine pharmacokinetics in depressed children and adolescents","volume":"38","author":"Findling","year":"1999","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2165\/00023210-199708020-00010","article-title":"Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder","volume":"8","author":"Foster","year":"1997","journal-title":"CNS drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1517\/14656566.2012.652085","article-title":"Paroxetine for the treatment of depression: a critical update","volume":"13","author":"Gibiino","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"B11","unstructured":"Product monograph-PAXIL CR\n            GlaxoSmithKline\n          2005"},{"key":"B12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.2147\/DDDT.S327506","article-title":"Modeling and simulation for individualized therapy of amisulpride in Chinese patients with schizophrenia: Focus on interindividual variability, therapeutic reference range and the laboratory alert level","volume":"15","author":"Huang","year":"2021","journal-title":"Drug Des. devel. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s00228-011-1073-9","article-title":"Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder","volume":"67","author":"Ishiguro","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s002280050163","article-title":"Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine","volume":"51","author":"Jeppesen","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/pst.373","article-title":"Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power","volume":"8","author":"Johnson","year":"2009","journal-title":"Pharm. Stat."},{"key":"B18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1124\/dmd.109.030551","article-title":"Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator","volume":"38","author":"Jornil","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.2147\/DDDT.S84718","article-title":"Exposure-outcome analysis in depressed patients treated with paroxetine using population pharmacokinetics","volume":"9","author":"Kim","year":"2015","journal-title":"Drug Des. devel. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2217\/pgs.10.128","article-title":"CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine","volume":"11","author":"Lin","year":"2010","journal-title":"Pharmacogenomics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1111\/bcp.13952","article-title":"Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients","volume":"85","author":"Lu","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/15622975.2019.1583373","article-title":"Psychopharmacology and ethnicity: A comparative study on Senegalese and Italian men","volume":"21","author":"Marazziti","year":"2020","journal-title":"World J. Biol. Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.5414\/cp201798","article-title":"Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine","volume":"51","author":"Mikami","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/FPC.0000000000000228","article-title":"Influence of the cytochrome P450 2D6 *10\/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis","volume":"26","author":"Nishimura","year":"2016","journal-title":"Pharmacogenet. Genomics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/PGPM.S60747","article-title":"Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders","volume":"7","author":"Saruwatari","year":"2014","journal-title":"Pharmgenomics. Pers. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00228-004-0792-6","article-title":"Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine","volume":"60","author":"Sawamura","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/clpt.1992.24","article-title":"Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism","volume":"51","author":"Sindrup","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/cpt.889","article-title":"Impact of CYP2D6 functional allelic variations on phenoconversion and drug-drug interactions","volume":"104","author":"Storelli","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B29","unstructured":"Paroxetine (marketed as paxil) information2015"},{"key":"B30","unstructured":"PAXIL CR\u00ae (PAX-il) (paroxetine hydrochloride) Controlled-Release Tablets2014"},{"key":"B31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1124\/jpet.115.223768","article-title":"Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine","volume":"354","author":"Uttamsingh","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1128\/AAC.01243-06","article-title":"Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects","volume":"51","author":"van der Lee","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1124\/dmd.105.004077","article-title":"In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude","volume":"33","author":"Venkatakrishnan","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e036412","DOI":"10.1136\/bmjopen-2019-036412","article-title":"Adverse effects information in clinical guidelines on pharmacological treatment of depression in children and adolescents: a systematic review","volume":"10","author":"Westergren","year":"2020","journal-title":"BMJ Open"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0181082","DOI":"10.1371\/journal.pone.0181082","article-title":"Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition","volume":"12","author":"Westin","year":"2017","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/sj.tpj.6500491","article-title":"Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy","volume":"9","author":"Wilkie","year":"2009","journal-title":"Pharmacogenomics J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.2147\/DDDT.S316110","article-title":"What to do about missed doses? A retrospective study of olanzapine in the elderly","volume":"15","author":"Xiao","year":"2021","journal-title":"Drug Des. devel. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/hup.1252","article-title":"Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders","volume":"26","author":"Yasui-Furukori","year":"2011","journal-title":"Hum. Psychopharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.966622\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:55:49Z","timestamp":1662944149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.966622\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":38,"alternative-id":["10.3389\/fphar.2022.966622"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.966622","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"article-number":"966622"}}